Gold prices bounce off 3-week lows; demand likely longer term
Daniel J. Lippis, Corporate Vice President of JAPAC at Edwards Lifesciences Corp (NYSE:EW), executed a series of stock transactions on April 8, 2025, according to a recent SEC filing. Lippis sold 300 shares of common stock at a price of $70.61 each, totaling approximately $21,183. This transaction was part of a pre-established Rule 10b5-1 trading plan. The sale price represents a premium to the current trading price of $67.07, with the stock currently showing signs of being slightly undervalued according to InvestingPro analysis.
In addition to the sale, Lippis also exercised 300 employee stock options at a price of $45.28 per share, which were acquired through the company's Employee Stock Purchase Plan. Following these transactions, Lippis holds 22,863 shares of Edwards Lifesciences common stock directly. The company maintains strong financial health with a current ratio of 4.18 and more cash than debt on its balance sheet. InvestingPro subscribers can access 8 additional key insights about Edwards Lifesciences, including detailed analysis of management's share buyback strategy and comprehensive valuation metrics.
In other recent news, Edwards Lifesciences reported strong financial results for the fourth quarter of 2024, exceeding analysts' expectations. The company achieved an adjusted earnings per share (EPS) of $0.59, surpassing the forecast of $0.55, and reported revenue of $1.39 billion, which was higher than the anticipated $1.36 billion. The Transcatheter Aortic Valve Replacement (TAVR) segment generated $1.04 billion in global sales, marking a 5.3% increase from the previous year. The Transcatheter Mitral and Tricuspid Therapies (TMTT) division also showed significant growth, with sales of $105.1 million, reflecting an 85% year-over-year increase.
Following these results, Canaccord Genuity raised its price target for Edwards Lifesciences to $71, maintaining a Hold rating, while Stifel reiterated a Buy rating with a $90 target. These developments come amid positive feedback from the medical community regarding the company's EVOQUE transcatheter tricuspid valve replacement system, which was approved by the FDA and launched in early 2024. Analysts from Stifel expressed optimism about the device's future, noting a robust market outlook for tricuspid valve replacement. The company maintains its financial guidance for 2025, with anticipated growth in its TAVR and TMTT segments, supported by various catalysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.